Anavex Life Sciences Announces New Study Supporting Blarcamesine As A Potential Alzheimer's Treatment

Anavex Life Sciences announced a new peer-reviewed study published by the University of California, which supports the hypothesis that disruption of neuronal homeostasis, specifically autophagy impairment, is a key factor in Alzheimer's disease pathology. The study, titled 'The microtubule nexus linking amyloid beta and tau: A simple and unifying theory for the underlying cause of Alzheimer's disease,' was published in the Proceedings of the National Academy of Sciences. This research may bolster the potential of Anavex's drug, Blarcamesine, as a treatment for Alzheimer's.